Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.

Bortolato M, Bini V, Tambaro S.

Pharmaceuticals (Basel). 2010 Aug 26;3(9):2799-2820. Review.

2.

Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms.

Gallo EF, Posner J.

Lancet Psychiatry. 2016 Jun;3(6):555-67. doi: 10.1016/S2215-0366(16)00096-1. Review.

3.

Endocannabinoid signalling in reward and addiction.

Parsons LH, Hurd YL.

Nat Rev Neurosci. 2015 Oct;16(10):579-94. doi: 10.1038/nrn4004. Review.

4.
5.

Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders.

Yıldız M, Vural M, Erdal ME, İzci Ay Ö, Yılmaz ŞG, Karababa İF, Selek S.

Iran J Reprod Med. 2015 Apr;13(4):221-6.

6.

Impulsivity, variation in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes, and marijuana-related problems.

Bidwell LC, Metrik J, McGeary J, Palmer RH, Francazio S, Knopik VS.

J Stud Alcohol Drugs. 2013 Nov;74(6):867-78.

7.

Evidence for a genetic component for substance dependence in Native Americans.

Ehlers CL, Gizer IR.

Am J Psychiatry. 2013 Feb;170(2):154-64. doi: 10.1176/appi.ajp.2012.12010113. Review.

8.

On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity.

Wiskerke J, van Mourik Y, Schetters D, Schoffelmeer AN, Pattij T.

Front Pharmacol. 2012 Jun 11;3:108. doi: 10.3389/fphar.2012.00108.

9.

Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.

Schacht JP, Hutchison KE, Filbey FM.

Neuropsychopharmacology. 2012 Oct;37(11):2368-76. doi: 10.1038/npp.2012.92.

10.

Allele-specific differences in activity of a novel cannabinoid receptor 1 (CNR1) gene intronic enhancer in hypothalamus, dorsal root ganglia, and hippocampus.

Nicoll G, Davidson S, Shanley L, Hing B, Lear M, McGuffin P, Ross R, MacKenzie A.

J Biol Chem. 2012 Apr 13;287(16):12828-34. doi: 10.1074/jbc.M111.336750.

11.

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Hillard CJ, Weinlander KM, Stuhr KL.

Neuroscience. 2012 Mar 1;204:207-29. doi: 10.1016/j.neuroscience.2011.11.020. Review.

12.

Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

Wiskerke J, Stoop N, Schetters D, Schoffelmeer AN, Pattij T.

PLoS One. 2011;6(10):e25856. doi: 10.1371/journal.pone.0025856.

13.

Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Serrano A, Parsons LH.

Pharmacol Ther. 2011 Dec;132(3):215-41. doi: 10.1016/j.pharmthera.2011.06.005. Review.

14.

Cannabinoid CB₂ receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice.

Navarrete F, Pérez-Ortiz JM, Manzanares J.

Br J Pharmacol. 2012 Jan;165(1):260-73. doi: 10.1111/j.1476-5381.2011.01542.x.

15.

Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index.

Baye TM, Zhang Y, Smith E, Hillard CJ, Gunnell J, Myklebust J, James R, Kissebah AH, Olivier M, Wilke RA.

Pharmacogenomics. 2008 Nov;9(11):1647-56. doi: 10.2217/14622416.9.11.1647.

Supplemental Content

Support Center